Picture [iito] No Tracking 650x80px
Person › Details

Philippe Dro (LimmaTech Biologics AG)

Dro, Philippe (LimmaTech Biologics 201505– before GlycoVaxyn CEO)


Organisations Organisation LimmaTech Biologics AG
  Former/major organisation GlycoVaxyn AG
  Group GlaxoSmithKline (GSK) (Group)
Products Product vaccine technology
  Product 2 vaccine

LimmaTech Biologics AG. (8/28/15). "Press Release: LimmaTech Biologics AG Starts Operating".

LimmaTech Biologics was founded in May 2015. In February 2015, GSK acquired GlycoVaxyn, a clinical stage biopharmaceutical firm focused on the research and development of next-generation bioconjugate vaccines using proprietary technology enabling biological synthesis of glyco-conjugate antigens. Following the acquisition, GSK commissioned GlycoVaxyn’s management team to create a new company, LimmaTech Biologics AG, to which GlycoVaxyn’s operational research business has been transferred. LimmaTech Biologics is not a GSK-owned company. GSK and LimmaTech Biologics have signed a research agreement with a minimum term of five years to allow the company to develop novel bioconjugate antigen-based vaccines exclusively for GSK to bolster GSK’s pipeline of innovative vaccines and to develop new products in other fields.

Under the terms of the agreement, GSK will retain full ownership of early stage bioconjugate antigens and candidate vaccines for diseases such as shigellosis, Streptococcus pneumoniae and Staphylococcus aureus infections, vaccines which were previously developed by GlycoVaxyn, as well as other candidates in the vaccine field including newly developed candidates. LimmaTech Biologics will be in a position to generate proprietary therapeutic products in areas outside of vaccines.

Veronica Gambillara Fonck, Managing Director, said: “We are extremely pleased with this research and development agreement between GSK and LimmaTech Biologics and this very innovative business relationship. This is a fantastic opportunity for our research organization to contribute to the development of an exciting new generation of vaccines. Whilst we aim to retain the agility and innovativeness of a small biotech company in LimmaTech, we will benefit tremendously from the support, expertise and sheer development power that GSK brings.”

The company will be overseen by an experienced Board of Directors with representatives from GSK Vaccines and from LimmaTech Biologics’ management.

About LimmaTech Biologics AG

LimmaTech Biologics AG was incorporated following the acquisition of GlycoVaxyn by GSK in February 2015 and is a clinical-stage biopharmaceutical company, developing recombinant vaccines for major infectious diseases using a technology previously developed by GlycoVaxyn and now owned by GSK. The company is primarily dedicated to applying this technology to the development of bioconjugate vaccines and will also generate proprietary therapeutic products in areas outside of vaccines.

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is a leader in vaccines. With a comprehensive portfolio of 40 vaccines for infants, adolescents and adults and 17 more in development, we have more than 16,000 people working worldwide to deliver over 2.5 million vaccines safely, every day, to people in 90% of the world’s countries. GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit

Record changed: 2018-09-28


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Philippe Dro

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top